3 results
The primary objective is to investigate the safety and tolerability of inhalation of glycopyrronium inhalation powder using different dosing regimens. The second objectives are to determine the decrease in drooling by using different dosing regimens…
Primary: To demonstrate the superiority of NVA237 50 *g o.d. compared to placebo in addition to background therapy with long acting B2 agonist/ inhaled corticosteroid (* 800 *g/day of budesonide or equivalent) in terms of trough FEV1 after 26 weeks…
The study contains 2 parts: Part 1 is the dose escalation part. Part 2 is the dose expansion part.The primary objective of part 1 is to determine recommended Phase 2 dose(s) (RP2Ds) of JNJ-78278343 by investigating the incidence and severity of AEs…